On May 10, 2021, Hong Tan, CEO of ET Healthcare, announced that Access Medical Systems (AMS), the parent company of ET Healthcare, has closed a new round of financing in a deal worth more than $100 million. The new funds will be used for research and development of new technologies and new products, global market development and production capacity enhancement.  

AMS has two sub-brands: ET Healthcare and Gator Bio, which are deployed in the two major areas of in vitro diagnostics and life sciences. With its innovative biosensing technology and detection platform, it is committed to building a new global market segment leader.

Hong Tan said to ET Healthcare and Gator Bio's WeChat public account: “I sincerely thank the people who participated in the financing of AMS. Through the close contact in the past few months, I have a deeper and more comprehensive understanding of these investment funds. I admire their serious work attitude and outstanding work ability. This is also one of the important factors for our happy cooperation this time.”

The core competitiveness of AMS comes from Test-On-A-Probe (TOP), a biosensor with more than 50 global patents. The TOP technology loads different detection techniques on a single probe to complete the analysis of proteins, antibodies, nucleic acids, small molecules and cells. So far, the company has successfully developed technology platforms such as fluorescence detection, chemiluminescence detection, and label-free detection on probes. Its original technology, industrialization capability and market potential have been fully verified in multiple market segments.